Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33411440

about

Novel agents in the treatment of multiple myeloma: a review about the future Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity European perspective on multiple myeloma treatment strategies in 2014 Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Clinical use of proteasome inhibitors in the treatment of multiple myeloma Trial Watch: Proteasomal inhibitors for anticancer therapy Esters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma Cells Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Multiple myeloma in the marrow: pathogenesis and treatments.Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party Salvage therapy of multiple myeloma: the new generation drugs.Current treatment landscape for relapsed and/or refractory multiple myeloma.A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.Bendamustine in multiple myeloma.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.An update in treatment options for multiple myeloma in nontransplant eligible patients.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.The proteasome and proteasome inhibitors in multiple myeloma.Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.

P2860

Q26745924-88D83BDB-F779-40F7-8574-480E3294DC0B Q26771331-3AE9F0DB-A7C6-401E-966D-E975A4792768 Q27005966-685576E7-B0D1-4743-896C-5C844363D141 Q27026478-449D1161-4517-4D2B-889D-20821BACBECA Q28080999-8CDE0444-7DB1-48C9-8BF6-734D94F28605 Q28082910-55176219-C72D-43DF-8A02-DA7C0E584038 Q28552720-D942325B-8344-4FA4-94A7-3475ABC0E2D1 Q30828090-7F649854-E527-40F5-8346-7AF585A7E34B Q33418389-73C87331-9DC4-4D6B-A4A5-A8BD8AD4142C Q33437691-D3643D13-B306-4124-8167-7B5302703DF4 Q33442039-9FB5F33C-34BA-45BC-9998-2064E918674D Q36725401-6C70E177-9712-46A1-8441-339AAFCA82A7 Q36799760-CDEDC1B5-3B9A-49AD-9FDF-DEAE8D6BFFC4 Q37313790-DF89D4D5-ED91-4F91-9826-FFAFA14FF79F Q37318682-C3A07782-3EE6-480C-AFEE-22698F7598A6 Q38223433-493700E0-D51A-481B-8BAF-846743EBF006 Q38271032-53D962E0-3CED-4411-9BAE-860E03F1D636 Q38394118-6725FDA2-862D-4B80-9962-6E93FD7F9E6C Q38530583-B43254AF-C374-4F91-A77F-BD18DD14F6AA Q38548134-9EDD7986-02B2-48C4-B1B3-BE064B21363F Q38561373-1C1EEF3A-2148-45E8-98FD-5B4FEB211170 Q38642648-FBB9AF0D-BBA2-4304-B821-034553A76641 Q38658649-31564E94-902D-4E7E-A785-24BAB695EABB Q38700745-82C1D3A5-67FD-4EA1-95B8-D602960581FA Q39124257-C0D2F49E-7B75-4971-B035-86270AE8504E Q39177792-F88B8B88-1082-46B4-8229-EE719CCF4E5D Q40047253-3B1594BE-C466-4EC2-9B21-81AEE649F9D3 Q40095723-288EE8A1-7579-4782-9C34-D9EB4E3233AE Q41044036-8D30D65B-9BC8-4B7B-B832-709D28EB43B7 Q41253617-7333F18E-E881-4592-A2FB-91088A281126 Q41602187-1D7FE6BF-BAFD-4B50-BB0D-F65CCCA803E0 Q41970310-907D01ED-49E1-4DD8-812B-93C22885A14F Q42046604-C79F654B-B353-4175-B37E-98C4C5390566 Q42292945-3258011C-11EF-4145-A6AA-4EBB55917A75 Q42379450-06225566-B04D-4393-B56C-31F3A0691DB8 Q42940540-E791B700-9F33-40D7-B1AF-3796CBE3CF55 Q47339695-E09D6C95-2AD9-4F5B-A3AB-D237CB3631A7 Q47563557-6C9C92AE-4339-4A53-BB63-AD30250CA2C9 Q48204298-6E609952-E696-4CE0-9642-6327EFF60802 Q52911976-533178E6-BEC0-4EFB-8BB8-11DA181E3FD5

P2860

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33411440

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Bendamustine-bortezomib-dexame ...... r refractory multiple myeloma.

@ast

Bendamustine-bortezomib-dexame ...... r refractory multiple myeloma.

@en

type

label

Bendamustine-bortezomib-dexame ...... r refractory multiple myeloma.

@ast

Bendamustine-bortezomib-dexame ...... r refractory multiple myeloma.

@en

prefLabel

Bendamustine-bortezomib-dexame ...... r refractory multiple myeloma.

@ast

Bendamustine-bortezomib-dexame ...... r refractory multiple myeloma.

@en

P1433

Q33411440-DCD17AC3-0C3B-44E8-9490-17A154E91056

P1476

Q33411440-461EB6C7-1CDC-486E-A868-D88654D939B2

P2093

Q33411440-0FC03BDB-38F3-4BB5-B9F6-3F05CCF02844

Q33411440-1BAC6A6C-B120-47C4-8061-B0AFFA31F26A

Q33411440-28898C6B-F69B-4F1F-8F60-41AB2BD6865E

Q33411440-32C97C60-F830-4A50-9D80-6A7163FF6803

Q33411440-607C5FF3-6595-4793-AEA7-40C321D0A18C

Q33411440-AD144F37-0EC2-4EDE-B250-ABDE77D9C034

Q33411440-B5CEA4FC-1258-408A-B4A7-7A456F2D41CF

Q33411440-CB3E4201-D9B6-471F-B5A7-C3503778A6E1

Q33411440-CDC4110F-4E03-49D9-81D1-FB7303AE1C83

Q33411440-EDC7CB90-7E3E-4AF8-9513-150AA1C38D61

P2860

Q33411440-0669DE47-1351-4443-8B79-0454514AE2E2

Q33411440-068B1085-4EED-4E2F-B2A6-80A3AB943359

Q33411440-09749FC1-C31A-4817-8FAB-E49751B97321

Q33411440-0B1940A2-CB4C-4482-90CE-9C9C5C612D93

Q33411440-0FBAD37B-54B0-47EC-AC8D-BC4285D85B48

Q33411440-187E7BB4-3E5F-4FB9-9826-2661DC62F7E1

Q33411440-28C19B5C-2E77-4EDB-94F0-2248BDA01286

Q33411440-5C8F76B2-1A95-4925-BDD4-F7910CC9DB81

Q33411440-5E8A39FB-5EA7-4AD5-B34B-DDF0688EA681

Q33411440-804FFBA3-F9F8-4D0C-9F40-5C4910D5D009

P304

Q33411440-682FEC2D-A5DC-435D-8D72-8BE5287E6C77

P31

Q33411440-94B7574D-31ED-45B6-9201-28C774DD30AB

P356

Q33411440-DF81AA7C-CDE8-4B25-8963-834881F60CF9

P407

Q33411440-476968FD-C354-4D39-9473-3FB387D87CC8

P433

Q33411440-912CF22C-EF3D-4402-96D2-23362C78D2C4

P478

Q33411440-27B1A0DB-0406-4537-8112-D60B556E9CAD

P50

Q33411440-7E27613D-F84B-4239-BE5C-C9D30B46388A

P577

Q33411440-5085B0F3-F5EA-4EF8-8A97-22091F3A26AF

P5875

Q33411440-3827171B-612B-4204-BB6B-A1A45D886F12

P698

Q33411440-AA496BB6-54A2-41F9-BF22-0D624A21B899

P921

Q33411440-80435CBD-3BB0-49F7-A24E-5309F34A6A98

P932

Q33411440-AACB08B1-B9F7-4F7E-A20E-89B7AF93B5AA

P356

BLOOD-2013-08-521468

P1433

P1476

Bendamustine-bortezomib-dexame ...... r refractory multiple myeloma.

@en

P2093

Adalbert Weißmann

http://www.w3.org/2001/XMLSchema#string

Adelheid Seebacher

http://www.w3.org/2001/XMLSchema#string

Clemens Leitgeb

http://www.w3.org/2001/XMLSchema#string

Elisabeth Rauch

http://www.w3.org/2001/XMLSchema#string

Hedwig Kasparu

http://www.w3.org/2001/XMLSchema#string

Ludek Pour

http://www.w3.org/2001/XMLSchema#string

Niklas Zojer

http://www.w3.org/2001/XMLSchema#string

Richard Greil

http://www.w3.org/2001/XMLSchema#string

Werner Linkesch

http://www.w3.org/2001/XMLSchema#string

Zdenek Adam

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

International uniform response criteria for multiple myeloma.

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.

P304

985-991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-08-521468

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258524223

http://www.w3.org/2001/XMLSchema#string

P698

24227817

http://www.w3.org/2001/XMLSchema#string

P921

P932

3924931

http://www.w3.org/2001/XMLSchema#string